AR065941A1 - Nuevas formulaciones para la provision de terapeuticas peptidicas antivirales. composicion. - Google Patents
Nuevas formulaciones para la provision de terapeuticas peptidicas antivirales. composicion.Info
- Publication number
- AR065941A1 AR065941A1 ARP080101399A ARP080101399A AR065941A1 AR 065941 A1 AR065941 A1 AR 065941A1 AR P080101399 A ARP080101399 A AR P080101399A AR P080101399 A ARP080101399 A AR P080101399A AR 065941 A1 AR065941 A1 AR 065941A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- composition according
- peptide
- antiviral
- administration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 16
- 239000003814 drug Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 230000000975 bioactive effect Effects 0.000 abstract 4
- 239000000463 material Substances 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 4
- 239000003443 antiviral agent Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones y métodos para su administracion como agentes terapéuticos. En particular, composiciones y su uso para la administracion de terapéuticas peptídicas antivirales. Reivindicacion 1: Una composicion caracterizada porque comprende unsolvente, un material gelante y un molécula bioactiva, en donde tras la administracion a un paciente, dicha composicion formas una matriz y provee una Cmáx de dicha molécula bioactiva de al menos 1 microg/ml dentro de 12 horas de administracionseguida de liberacion sostenidacon niveles plasmáticos de al menos 1 microg/ml durante al menos 7 días. Reivindicacion 2: Una composicion caracterizada porque comprende un solvente, un material gelante y un péptido seleccionado de T20, T1249,T897, T2635, T999 y T1144, o una de sus combinaciones. Reivindicacion 12: La composicion de acuerdo con la reivindicacion 2, caracterizada porque el péptido es T1144. Reivindicacion 14: La composicion de acuerdo con la reivindicacion 2,caracterizada porque dicha composicion también comprende al menos otra molécula bioactiva. Reivindicacion 15: La composicion de acuerdo con la reivindicacion 14, caracterizada porque la otra molécula bioactiva es un agenteantiviral. Reivindicacion 17: La composicion de acuerdo con la reivindicacion 15, caracterizada porque el agente antiviral es una citoquina. Reivindicacion 18: La composicion de acuerdo con la reivindicacion 15, caracterizada porque el agenteviral es inhibidor transcriptasa inversa. Reivindicacion 19: La composicion de acuerdo con la reivindicacion 15, caracterizada porque el agente antiviral es un inhibidor de cubierta de mARN viral. Reivindicacion 32: Un método para la liberacionsostenida de un péptido en un paciente caracterizado porque comprende administrar al paciente una composicion que comprenden un solvente, un material gelante y un péptido seleccionado de T20, T1249, T897, T2635, T999 y T1144, o una de suscombinaciones. Reivindicacion 38: Un método para aliviar un síntoma asociado con una infeccion por HIV, caracterizadol porque comprende administrar a un paciente infectado por HIV una composicion que comprende un solvente, un material gelante y unpéptido seleccionado de T20, T1249, T897, T2635, T999 y T1144, o una de sus combinaciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92170407P | 2007-04-03 | 2007-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065941A1 true AR065941A1 (es) | 2009-07-15 |
Family
ID=39831248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101399A AR065941A1 (es) | 2007-04-03 | 2008-04-03 | Nuevas formulaciones para la provision de terapeuticas peptidicas antivirales. composicion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090068243A1 (es) |
| EP (1) | EP2139526A4 (es) |
| JP (1) | JP2010523564A (es) |
| KR (1) | KR20100016142A (es) |
| CN (1) | CN101678125A (es) |
| AR (1) | AR065941A1 (es) |
| BR (1) | BRPI0809995A2 (es) |
| CA (1) | CA2682848A1 (es) |
| MX (1) | MX2009010689A (es) |
| TW (1) | TW200902043A (es) |
| WO (1) | WO2008124013A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2907524A1 (en) | 2007-05-25 | 2015-08-19 | RB Pharmaceuticals Limited | Sustained delivery formulations of risperidone compounds |
| BRPI0817697A2 (pt) * | 2007-09-25 | 2015-04-07 | Trimeris Inc | Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo |
| WO2010047826A2 (en) * | 2008-10-24 | 2010-04-29 | Trimeris, Inc. | Dosing regimens and dosage formulations of an antiviral peptide therapeutic |
| WO2012074883A1 (en) * | 2010-11-24 | 2012-06-07 | Durect Corporation | Biodegradable drug delivery composition |
| EP2782590A4 (en) * | 2011-11-23 | 2016-08-03 | Durect Corp | BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS |
| CN105163719B (zh) | 2013-03-11 | 2019-03-08 | 度瑞公司 | 包含高粘度液体载体的可注射控制释放组合物 |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| CN109320593A (zh) * | 2018-11-05 | 2019-02-12 | 中国人民解放军军事科学院军事医学研究院 | 抑制hiv感染的螺旋多肽及其用途 |
| CN112851789B (zh) * | 2021-02-04 | 2022-10-18 | 大理大学 | 一种脑靶向hiv进入抑制剂多肽及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016273A (en) * | 1975-07-16 | 1977-04-05 | American Cyanamid Company | Sustained release forms of certain oxazepines for parenteral administration |
| JPS55154991A (en) * | 1979-05-23 | 1980-12-02 | Hisamitsu Pharmaceut Co Inc | Beta-d-fructopyranoside derivative |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
| US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
| US5234520A (en) * | 1987-03-20 | 1993-08-10 | Morgan Adhesives Co. | Method of making an adhesive construction |
| US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5462863A (en) * | 1989-02-09 | 1995-10-31 | Development Center For Biotechnology | Isolation of Hepatitis B surface antigen from transformed yeast cells |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| AU2791792A (en) * | 1991-10-04 | 1993-05-03 | Robert H. Cornett | Approaching emergency vehicle warning system |
| ES2139017T3 (es) * | 1992-07-20 | 2000-02-01 | Univ Duke | Compuestos que inhiben la replicacion del vih. |
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5589167A (en) * | 1993-02-23 | 1996-12-31 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| GB9404270D0 (en) * | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US5474058A (en) * | 1994-11-30 | 1995-12-12 | Thayer Medical Corporation | MDI ventilator dispenser with bi-directional nozzle |
| US6004549A (en) * | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| CA2224008C (en) * | 1995-06-07 | 2009-08-18 | Trimeris, Inc. | The treatment of hiv and other viral infections using combinatorial therapy |
| US6413536B1 (en) * | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| US20020064546A1 (en) * | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| US6191107B1 (en) * | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
| WO1999033489A1 (fr) * | 1997-12-26 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales a liberation prolongee |
| US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6541020B1 (en) * | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
| WO2001078683A2 (en) * | 2000-04-19 | 2001-10-25 | Genentech, Inc. | Sustained release formulations comprising growth hormone |
| EP1379197A4 (en) * | 2001-03-23 | 2009-06-03 | Durect Corp | DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM |
| ES2554106T3 (es) * | 2001-06-21 | 2015-12-16 | Genentech, Inc. | Formulación de liberación sostenida |
| US6733714B2 (en) * | 2001-08-13 | 2004-05-11 | Edwin J. Oakey | Method for forming high-impact, transparent, distortion-free polymeric material |
| CN1100564C (zh) * | 2001-08-29 | 2003-02-05 | 周根发 | 用于治疗hiv感染的药物、其组合物及其用途 |
| US7045552B2 (en) * | 2002-09-27 | 2006-05-16 | Trimeris, Inc. | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy |
| BRPI0418304A (pt) * | 2004-01-07 | 2007-05-02 | Trimeris Inc | peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv |
| CN101132812A (zh) * | 2004-03-15 | 2008-02-27 | 阿拉巴马耐科塔医药公司 | Hiv进入抑制剂的聚合物基组合物和结合物 |
| CA2556032A1 (en) * | 2004-03-15 | 2005-09-29 | Trimeris, Inc. | Site-specific chemical modification of hiv gp41-derived peptides |
| CN103007288B (zh) * | 2007-05-18 | 2015-02-11 | 杜雷科特公司 | 改进的贮库制剂 |
| BRPI0817697A2 (pt) * | 2007-09-25 | 2015-04-07 | Trimeris Inc | Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo |
-
2008
- 2008-04-02 CN CN200880018701A patent/CN101678125A/zh active Pending
- 2008-04-02 US US12/080,404 patent/US20090068243A1/en not_active Abandoned
- 2008-04-02 CA CA002682848A patent/CA2682848A1/en not_active Abandoned
- 2008-04-02 JP JP2010502128A patent/JP2010523564A/ja active Pending
- 2008-04-02 WO PCT/US2008/004307 patent/WO2008124013A1/en not_active Ceased
- 2008-04-02 KR KR1020097022905A patent/KR20100016142A/ko not_active Withdrawn
- 2008-04-02 EP EP08742498A patent/EP2139526A4/en not_active Withdrawn
- 2008-04-02 MX MX2009010689A patent/MX2009010689A/es not_active Application Discontinuation
- 2008-04-02 BR BRPI0809995-2A patent/BRPI0809995A2/pt not_active IP Right Cessation
- 2008-04-03 AR ARP080101399A patent/AR065941A1/es not_active Application Discontinuation
- 2008-04-03 TW TW097112437A patent/TW200902043A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20090068243A1 (en) | 2009-03-12 |
| CN101678125A (zh) | 2010-03-24 |
| CA2682848A1 (en) | 2008-10-16 |
| MX2009010689A (es) | 2009-12-14 |
| TW200902043A (en) | 2009-01-16 |
| JP2010523564A (ja) | 2010-07-15 |
| EP2139526A4 (en) | 2010-07-14 |
| BRPI0809995A2 (pt) | 2015-07-21 |
| KR20100016142A (ko) | 2010-02-12 |
| WO2008124013A1 (en) | 2008-10-16 |
| EP2139526A1 (en) | 2010-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065941A1 (es) | Nuevas formulaciones para la provision de terapeuticas peptidicas antivirales. composicion. | |
| PE20241760A1 (es) | Compuestos antivirales que contienen nitrilo | |
| CO2022018715A2 (es) | Análogos de nucleósido de 1’-ciano y usos de los mismos | |
| DOP2014000067A (es) | Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv | |
| UY27874A1 (es) | Cster de 2' -c -netil- 3 ' -o-l-valina de ribofuranosilcitidina para el tratamiento de infecciones de flaviviridae. | |
| BRPI0414907A (pt) | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas | |
| PE20080612A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| AR126239A1 (es) | Región 5 no traducida y región 3 no traducida no naturales y uso de estas | |
| MX2019010171A (es) | Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular. | |
| AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
| CL2023000087A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| UY31280A1 (es) | Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada | |
| AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| PE20240808A1 (es) | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| AR066677A1 (es) | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| PE20090653A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| CL2008002466A1 (es) | Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |